1. Introduction {#sec1-materials-10-00488}
===============

Bioactive glasses (BGs) have received considerable attention since they were developed \[[@B1-materials-10-00488]\]. Due to their superior bioactivity and other properties, such as non-toxicity, biocompatibility, and degradability, they have been applied to numerous tissue engineering applications, such as bone replacement, tooth repair, and drug-carrying materials \[[@B2-materials-10-00488],[@B3-materials-10-00488]\]. Osteomyelitis, a serious problem, may be induced by bone filling and bone replacement during surgery \[[@B4-materials-10-00488]\]. A local drug delivery system providing antibiotics or growth factors needs to be introduced \[[@B5-materials-10-00488]\]. Therefore, a material must be bioactive and have a higher specific surface area and various pore sizes for this purpose.

In order to increase the surface area of BGs effectively, the idea of adding surfactant as a structural template to prepare mesoporous bioactive glasses (MBGs) was introduced by Yan et al. in 2004 \[[@B6-materials-10-00488]\]. His work successfully demonstrated the synthesis of MBGs using non-ionic tri-block copolymer based on two monomers, ethylene oxide and propylene oxide (denoted as EO and PO), which results in a well-ordered mesoporous structure and a high specific surface area of up to 300 m^2^/g. With increased surface area, MBGs exhibit an increase in the hydroxyapatite (HA) formation rate during bioactivity tests, in which the specimens are immersed in simulated body fluid (SBF) \[[@B7-materials-10-00488]\]. Furthermore, the mesoporous structure has been found to be suitable for hosting and delivering various medicines. The feasibility of this concept was demonstrated by Vallet-Regi et al. in 2001 \[[@B8-materials-10-00488]\]. They used MBGs to host and deliver the drug ibuprofen, an analgesic drug used for treating pain, fever, and inflammation, in in vitro tests. Moreover, Perez et al. recently used MBG as the carriers to deliver growth factors and stem cells and found that the MBG carriers showed substantial improvements in cellular spreading and population up to 7 days, which provides the possible applications for tissue engineering \[[@B9-materials-10-00488]\]. Since then, many investigations have been conducted in this area to develop different types of MBGs with various porous structures and functionalities for sustained drug release.

Presently, the development of MBGs for drug delivery systems can be divided into two major parts. Numerous researchers have focused on increasing the surface area of MBGs by either varying the chemical compositions or applying different surfactants \[[@B10-materials-10-00488],[@B11-materials-10-00488]\]. Both approaches have achieved great success in increasing the specific surface area. On the other hand, the relation between pore size and drug release rate has also been studied. Horcajada et al. demonstrated that the delivery rate decreases from 24 to 5 mg/h as the pore size decreases from 3.6 to 2.5 nm \[[@B12-materials-10-00488]\], while Vallet-Regi et al. tabulated several mesoporous materials and their drug loading abilities in 2007 \[[@B13-materials-10-00488]\]. However, rare studies have reported on the correlation between pore size and bioactivity, which we believe is a crucial question when it comes to applications for bone implants. For example, for tissue engineering, both drug releasing effects (pore size) \[[@B12-materials-10-00488]\] and bone regeneration effects (bioactivity) (Perez, et al. \[[@B9-materials-10-00488]\]) are important, which needs to be considered. Compared to commonly used drug-carrying materials such as MCM-41 or SBA-15, bioactive MBGs have the potential to be applied as drug-carrying materials in bone implant surgeries. Therefore, the correlation of pore size and bioactivity must be examined in relation to both the drug carrying ability and the bioactivity of MBGs.

Several studies have applied various surfactants to prepare MBGs, and numerous results have been reported \[[@B6-materials-10-00488],[@B14-materials-10-00488],[@B15-materials-10-00488],[@B16-materials-10-00488],[@B17-materials-10-00488],[@B18-materials-10-00488],[@B19-materials-10-00488],[@B20-materials-10-00488]\]. However, most of the studies used sol-gel to synthesize the MBGs \[[@B11-materials-10-00488],[@B21-materials-10-00488]\], and those studies were all focused on the effect of increasing the surface area on bioactivity \[[@B11-materials-10-00488],[@B22-materials-10-00488]\]. In contrast, this study employed spray pyrolysis (SP), which is a continuous process with rapid heating and cooling \[[@B23-materials-10-00488]\]. This process preserves more metastable siloxane groups in the resulting MBGs \[[@B24-materials-10-00488]\]. These groups act as nucleation sites and help HA formation \[[@B25-materials-10-00488]\].

In this study, three MBG powders were synthesized using SP with three surfactants with different EO and PO ratios. The characterizations of phase composition, surface morphology, inner structure, and specific surface area were carried out by X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and analysis of nitrogen adsorption/desorption isotherms, respectively. In addition, in vitro bioactivity was assessed by immersing the powders in SBF and evaluating the HA formation against the as-prepared glasses. Finally, the correlation between pore size and bioactivity was investigated, and pore formation mechanisms of the surfactant are proposed.

2. Results {#sec2-materials-10-00488}
==========

2.1. Phase Composition {#sec2dot1-materials-10-00488}
----------------------

[Figure 1](#materials-10-00488-f001){ref-type="fig"} shows three XRD patterns of as-prepared powders treated with the L121, P123, and F127 surfactants. All XRD patterns present the absence of any crystalline phase, with only a broad band existing between 20.0° and 37.0°. Thus, amorphous MBG powders were prepared successfully.

2.2. Morphology {#sec2dot2-materials-10-00488}
---------------

SEM images of L121-, P123- and F127-treated MBG powders are shown in [Figure 2](#materials-10-00488-f002){ref-type="fig"}, demonstrating that the particles of all MBG powders were spherical. [Figure 2](#materials-10-00488-f002){ref-type="fig"}a shows that the MBG powder treated with L121 surfactants exhibited the two morphologies of smooth sphere (denoted Type I) and wrinkled sphere (denoted Type II). The corresponding sizes of Type I and Type II particles ranged from 0.2 to 2.4 μm and from 0.2 to 2.1 μm, respectively. For the P123- and F127-treated MBG powders, the same surface morphologies of Type I and Type II and similar particle sizes were observed, as shown in [Figure 2](#materials-10-00488-f002){ref-type="fig"}b,c. The morphology and particle size results suggest that the three surfactant-treated MBG powders may have had the same particle formation mechanism. Furthermore, the proportions of both morphologies for all the MBG powders were measured statistically and are plotted in [Figure 3](#materials-10-00488-f003){ref-type="fig"}. That figure shows that the volume proportions of smooth particles (Type I) were 62.5%, 64.9%, and 81.6% for L121-, P123-, and F127-treated MBG powders, whereas the volume proportions of wrinkled particles (Type II) were 37.5%, 35.1%, and 18.4%. The results indicated that the proportion of Type I increased (and the proportion of Type II decreased) as the EO number increased (5 for L121, 20 for P123, and 106 for F127).

[Figure 4](#materials-10-00488-f004){ref-type="fig"} presents typical TEM micrographs of various surfactant-treated MBG powders. That figure confirms the morphologies of the smooth sphere and the wrinkled sphere observed by SEM ([Figure 2](#materials-10-00488-f002){ref-type="fig"}). Furthermore, in order to observe the detailed pore structure, the illumination of the micrographs was adjusted so that they were slightly under focused, as shown in the high resolution TEM (HRTEM) images inserted in the top right corner of [Figure 4](#materials-10-00488-f004){ref-type="fig"}. It should be noted that the contrasts in the TEM micrographs are associated with the thickness/mass of the particles. The dark contrast represents a thicker/heavier region, indicating a solid region, whereas a bright contrast represents a thinner/lighter region, indicating a pore region. Therefore, the HRTEM images in [Figure 4](#materials-10-00488-f004){ref-type="fig"} suggest that all MBG powders exhibited a mesoporous structure, and that pore size varied from 1 to 10 nm. Moreover, from the HRTEM images in [Figure 4](#materials-10-00488-f004){ref-type="fig"}, it appears that the L121-treated MBG powder had larger bright areas (i.e., larger pores) than did the P123- and F127-treated MBG powders ([Figure 4](#materials-10-00488-f004){ref-type="fig"}b,c). This difference implies that the L121 surfactant produced the largest pores.

2.3. Particle Size Distribution and Specific Surface Area {#sec2dot3-materials-10-00488}
---------------------------------------------------------

The pore size histograms of the surfactant-treated MBG powders are shown in [Figure 5](#materials-10-00488-f005){ref-type="fig"}. The graphs indicate that all MBG powders exhibited a normal distribution. The pore sizes of L121-, P123-, and F127-treated MBGs ranged from 4--16, 1--10, and 1--8 nm with a decreasing trend (*d*~50~ = 8.7 nm, *d*~50~ = 4.0 nm, and *d*~50~ = 4.1 nm for the L121-, P123- and F127-treated MBG powders). In addition, the L121-treated MBG powder demonstrated the largest pore size, 8.9 ± 1.4 nm, whereas the P123- and F127-treated MBG powders had smaller pore sizes of 4.5 ± 1.0 and 4.1 ± 1.1 nm, respectively. The statistical results revealed that a higher EO number of the surfactants led to a smaller pore size. Furthermore, the BET data show the pore sizes of 8.4 ± 0.2, 7.2 ± 0.2, and 7.2 ± 0.2 nm, respectively, which reveals a similar trend (L121-treated MBG \> P123-treated MBG \~F127-treated MBG) as the HRTEM data. Additionally, BET measurement revealed that the specific surface areas of the L121-, P123-, and F127-treated MBG powders were 137, 151, and 157 m^2^/g, respectively, and the pore volume values for the L121-, P123-, and F127-treated MBG powders were 0.082, 0.092, and 0.079 cm^3^/g, respectively, indicating that these three MBG powders had similar specific surface areas and pore volume values.

2.4. In Vitro BioactivyTests {#sec2dot4-materials-10-00488}
----------------------------

Bioactivity tests were carried out by XRD with all the MBG powders after immersion in SBF. After immersion in SBF for 12 h, the growth of HA was observed with XRD patterns, as shown in [Figure 6](#materials-10-00488-f006){ref-type="fig"}. The diffraction peaks of 25.9°, 28.1°, 29.3°, 31.8°, 32.2°, 33.7°, 39.4°, 46.7°, and 49.6° were identified as the (002), (102), (210), (211), (112), (302), (310), (213), and (004) planes of HA (JCPDS number: 09-0432). The XRD results demonstrated that the L121-treated MBG powder had sharper and more intense peaks at (002) and (211) than did the P123- and F127-treated MBG powders, indicating higher crystallinity of HA, which corresponds to higher bioactivity \[[@B26-materials-10-00488]\]. To quantify the bioactivity differences, the integration of the diffraction peak area was measured. The values for the (211) peak, main HA diffraction, were 2317, 1843, and 1822 counts for the L121-, P123-, and F127-treated MBG powders, respectively. Additionally, the values for the (002) peak, the second largest peak of HA, were 1608, 1314, and 1261 counts for the L121-, P123-, and F127-treated MBG powders, following the same trend as the (211) peak. Thus, the order of both the (211) and (002) peak areas were L121-treated MBG \> P123-treated MBG \> F127-treated MBG. Therefore, the order of bioactivity was L121-treated MBG \> P123-treated MBG \> F127-treated MBG. In conclusion, the bioactivity tests showed that the surfactants with the smaller EO numbers resulted in better bioactivity.

Furthermore, crystallite sizes of MBG were acquired using XRD and TEM. Initially, from the XRD patterns, based on the Scherrer equation, the crystallite sizes of L121-, P123-, and F127-treated MBG powders were 22.4 ± 12.4, 16.4 ± 1.5, and 17.2 ± 2.5 nm, respectively. In addition, [Figure 7](#materials-10-00488-f007){ref-type="fig"} shows the TEM images and the diffraction patterns of MBG powders immersed in the SBF solution for 12 h. To the eye, it is clear that L121-, P123-, and F127-treated MBG powders were covered by some nanocrystals; the indexed SAED patterns reveal that these nanocrystals are HA crystals. Consequently, the TEM images show that the crystallite size ranges of immersed L121-, P123-, and F127-treated MBG powders were 14--20, 12--19, and 7--16 nm, which agrees with the XRD result ([Figure 6](#materials-10-00488-f006){ref-type="fig"}).

3. Discussion {#sec3-materials-10-00488}
=============

The first issue to discuss is the SP formation mechanism of MBG powders. In a typical SP process, two common mechanisms responsible for the formation of the particles are "one-particle-per-drop" and "gas-to-particle" \[[@B27-materials-10-00488]\]. In the former, micron-sized droplets atomized by an ultrasonic nebulizer are directly converted into oxide particles. In the latter, nano-sized particles (\<0.1 μm) condense from the gas phase \[[@B28-materials-10-00488]\]. Based on the SEM observations, all the surfactant-treated MBG powders had an average particle size of \~600 nm, indicating that all the MBG powders formed via the "one-particle-per-drop" mechanism \[[@B27-materials-10-00488]\]. As shown in the SEM and TEM images ([Figure 2](#materials-10-00488-f002){ref-type="fig"} and [Figure 4](#materials-10-00488-f004){ref-type="fig"}), all the MBG powders had two types of particle morphologies, the smooth sphere (Type I) and the wrinkled sphere (Type II). The Type I and Type II particles were similar in size, indicating that there was no obvious correlation between morphology and particle size. The formation of Type I particles followed the typical SP precursor mechanism of precursor volume precipitation \[[@B27-materials-10-00488],[@B29-materials-10-00488]\]. The Type II particles formed because of the high surfactant concentration of those droplets, which aggregated on the surface via the SP precursor mechanism of surface precipitation \[[@B30-materials-10-00488]\]. After the calcination stage of the SP process, the aggregated surfactants were burned out, which resulted in the wrinkled surface morphology.

The second issue to discuss is the correlation of the EO number, the morphology, the pore size, and the bioactivity, as shown in [Figure 8](#materials-10-00488-f008){ref-type="fig"}. To begin with, the statistical measurement of the morphology proportions, shown in [Figure 3](#materials-10-00488-f003){ref-type="fig"}, indicated that, when the EO number of the surfactant increased, the proportion of Type II particles decreased. For example, the L121-treated MBG (EO number of 5) had the highest proportion of Type II particles, but the F127-treated MBG (EO number of 127) had the smallest proportion of these particles. As discussed above, the Type II morphology is attributed to the surfactant aggregation, and consequently, the higher proportion of Type II particles suggests more surfactant aggregation. Therefore, the L121 specimen had more aggregation than did the P123 and F127 specimens. The reason is that these three precursor solutions contained the same weight of surfactants. Since the average molar weights of L121, P123, and F127 were 4400, 5800, and 12,600, the molar concentration order of the surfactants was L121 \> P123 \> F127. It follows that a higher surfactant concentration increased the probability of aggregation (aggregation order of L121 \> P123 \> F127). Additionally, the aggregation order affected the pore size of the MBG particles. It is well known that all surfactants burn out to form pores in the calcinations step of SP, and the aggregated surfactants occupied more volume to form the larger pores. As shown in [Figure 5](#materials-10-00488-f005){ref-type="fig"}, the pore size order of L121 \> P123 \> F127 followed the same trend of aggregation order, which supports this argument. Finally, a higher EO number led to a lower Type II proportion and a smaller pore size, as shown in [Figure 8](#materials-10-00488-f008){ref-type="fig"}a. Finally, the schematic diagram of the formation mechanisms for the L121-, P123-, and F127-treated MBG powders is shown in [Figure 9](#materials-10-00488-f009){ref-type="fig"}.

The third issue is bioactivity. As mentioned before, previous studies focused only on the effect of the surface area on bioactivity \[[@B11-materials-10-00488],[@B14-materials-10-00488]\]. However, we believe that not only the surface area but also the pore size plays an important role in the bioactivity. [Figure 8](#materials-10-00488-f008){ref-type="fig"}b illustrates the relationship between pore size and bioactivity; it is clear that a larger pore size leads to better HA crystallinity (i.e., better bioactivity). One possible explanation is that larger pores provide more space for HA, whereas smaller pores may limit the growth of HA. In summary, MBG powders with larger pores can be prepared using surfactants with a lower EO number, and such MBG powders exhibit better bioactive properties. Therefore, they are potential candidates for drug delivery applications.

4. Materials and Methods {#sec4-materials-10-00488}
========================

4.1. Synthesis {#sec4dot1-materials-10-00488}
--------------

The MBG powders (70 mol%SiO~2~, 25 mol%CaO, and 5 mol%P~2~O~5~) were prepared from three distinct non-ionic tri-block surfactants of L121 (EO~5~PO~70~EO~5~, Sigma-Aldrich, St. Louis, MO, USA), P123 (EO~20~PO~70~EO~20~, Sigma-Aldrich, St. Louis, MO, USA), and F127 (EO~106~PO~70~EO~106~, BASF, Florham Park, NJ, USA) using SP. Tetraethyl orthosilicate (TEOS, Si(OC~2~H~5~)~4~, 99.9 wt %, Showa, Japan), calcium nitrate tetrahydrate (CN, Ca(NO~3~)~2~·4H~2~O, 98.5 wt %, Showa, Japan), and triethyl phosphate (TEP, (C~2~H~5~)~3~PO~4~, 99.0 wt %, Alfa Aesar, Ward Hill, MA, USA) were used as the sources for Si, Ca, and P, respectively. All MBG precursors, containing 44 wt % surfactant and 56 wt % Si, Ca, and P precursor mixture, were dissolved in 60.00 g of ethanol combined with 1.00 g of 0.5 M HCl and stirred at room temperature for 24 h to form the final precursor solution. For the SP process, the precursor solution was dispersed into fine droplets using an ultrasonic nebulizer (King Ultrasonic Co., Taiwan) at a frequency of 1.65 MHz. The droplets went through the thermal treatments of preheating, calcining, and cooling in a tube furnace (D110, Dengyng, Taiwan) at 400, 700, and 500 °C, respectively. The surfaces of the particles were then charged by electrons released from tungsten corona wire at high voltage (16 kV). After that, the negative-charged powders were neutralized and condensed in an earthed stainless steel collector. Finally, the powders were collected and annealed at 600 °C for 1 h to prevent carbon contamination.

4.2. Characterization {#sec4dot2-materials-10-00488}
---------------------

Initially, the phase compositions of the MBG powders were indexed using an X-ray diffractometer (D2 Phaser, Bruker, Germany). Then, the surface morphologies and inner structures were examined with a scanning electron microscope (SEM, JSM-6500F, JEOL, Japan) and a transmission electron microscope (Tecnai G2 F20, FEI, Portland, OR, USA), respectively. In addition, the particle size distributions and pore sizes were obtained as averages of more than 100 particles and 100 pores in SEM and TEM images, respectively. The specific surface areas, pore volume, and pore sizewere measured using the Brunauer--Emmett--Teller (BET) method with nitrogen as an absorbent. The nitrogen adsorption/desorption isotherms were obtained at −196 °C on a constant-volume adsorption apparatus (Tristar, Micromeritics, Norcross, GA, USA). As-prepared specimens were degassed at 150 °C for 3 h before measurements.

The in vitro bioactivity tests of the MBG powders were performed with SBF with an ionic concentration nearly equal to that of human plasma \[[@B7-materials-10-00488]\]. The three MBG specimens were prepared by immersing the MBG powders in SBF at a solid to liquid ratio of 1 mg to 1 mL and held at 37 °C for 12 h, since these three specimens exhibited similar specific surface areas \[[@B31-materials-10-00488]\]. The powders were then washed twice with acetone and once with DI water before drying at room temperature for one day. Then, XRD, TEM, and selected area electron diffraction (SAED) were used to characterize the formation of HA.

5. Conclusions {#sec5-materials-10-00488}
==============

Three MBG powders were prepared by SP from three distinct surfactants with various EO numbers (L121, P123, and F127), and the MBG structures, including the phase composition, morphology, pore size, and specific surface area, were characterized using XRD, SEM, TEM, and BET, respectively. The bioactive properties of these three powders were observed to be correlated to the corresponding MBG structures. The experimental data revealed that a smaller EO number of surfactant leads to (i) a higher probability of aggregation; (ii) a higher proportion of wrinkled sphere particles; (iii) a larger pore size; and (iv) better bioactivity. In summary, the relationship of MBG pore size and bioactivity has been correlated, and this correlation should provide useful information for developing future drug carriers.
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![(**a**) Type II proportion and pore size as the function of EO number; and (**b**) the (211) peak intensity of HA as the function of pore size.](materials-10-00488-g008){#materials-10-00488-f008}
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